GlassScriptPhysician profile
Nicole Hughes
NPI 1669701215
$14,076.86
in general payments reported to CMS, 2019-2025
22 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,581 · 2022: $6,710 · 2023: $2,226 · 2024: $280 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,636 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,636.08 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $5,323.18 | 2021-2023 | Uplizna |
| Genentech USA, INC. | $2,057.78 | 2021-2023 | Ocrevus, Enspryng |
| Emd Serono, INC. | $1,677.70 | 2021-2023 | Mavenclad |
| Biogen, INC. | $1,411.81 | 2021-2025 | Tysabri, Leqembi, Vumerity |
| Lilly USA, LLC | $530.19 | 2024-2025 | Kisunla |
| Genzyme Corporation | $453.97 | 2021-2022 | |
| Celgene Corporation | $452.77 | 2021-2023 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $370.64 | 2021-2022 | |
| Eisai INC. | $351.90 | 2024-2025 | |
| Abbvie INC. | $327.47 | 2025 | |
| Novartis Pharmaceuticals Corporation | $301.06 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $240.48 | 2022-2023 | |
| Banner Life Sciences, LLC | $169.89 | 2021-2023 | |
| Tg Therapeutics, INC. | $118.75 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $93.88 | 2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $70.33 | 2023-2025 | Xeomin, Inbrija |
| C2n Diagnostics, LLC | $27.14 | 2025 | Precivityad2 |
| Xeris Pharmaceuticals, INC. | $24.56 | 2025 | Keveyis |
| Amneal Pharmaceuticals LLC | $21.67 | 2025 | Crexont |
| Insightec,INC | $20.78 | 2025 | Exablate |
| Cala Health, INC. | $17.97 | 2025 | Cala Kiq |
| Amgen INC. | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.